Evaxion Biotech A/S
NASDAQ:EVAX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Evaxion Biotech A/S
Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
CEO Transition: Dr. Helen Tayton-Martin will become CEO on November 24, bringing significant biotech leadership experience; Birgitte Rono will return to CSO.
MSD Partnership: MSD (Merck) exercised its option on EVX-B3, marking the first AI-discovered vaccine candidate in-licensed by a major pharma and bringing in a $7.5 million fee.
Cash Runway: Cash runway now extended into the second half of 2027, supported by the MSD deal, warrant exercises, and EIB debt conversion.
R&D Milestones: Two-year Phase II data on EVX-01 melanoma vaccine showed a 75% response rate and strong sustained T cell activity; new EVX-04 AML vaccine added to pipeline.
AI Platform Upgrade: Automated vaccine design module launched, reducing development time and enabling potential external partnerships.
Future Revenue Potential: MSD deal could generate up to $592 million in future milestone payments.
Active Partnerships: Multiple partnership discussions underway across oncology, infectious disease, target discovery, and platform capabilities.
